At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Tanezumab 10 mg IV +1 moredrug
Likely dose
Tanezumab 10 mg IVfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER EFFICACY AND SAFETY STUDY OF TANEZUMAB AS ADD-ON THERAPY TO OPIOID MEDICATION IN PATIENTS WITH PAIN DUE TO BONE METASTASES
In Brief
A Phase 2 clinical trial evaluating Tanezumab 10 mg IV and IV Placebo for tanezumab for Neoplasm Metastasis and Palliative Care. Completed, enrolled 59 participants across 39 sites in 13 countries.
Detailed Summary
The purpose of this study is to investigate the safety and efficacy of tanezumab in combination with opioids in treating pain due to cancer that has spread to bone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm Metastasis, Palliative Care
CountriesAustria, Bosnia and Herzegovina, Croatia, France, Hungary, India, Latvia, Mexico, Peru, Poland, Slovakia, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartApr 2009
Primary CompletionDec 2011
Study CompletionFeb 2012
TodayJul 2026
First PostedOct 17, 2007
Enrollment StartApr 29, 2009
Primary CompletionDec 24, 2011
Study CompletionFeb 7, 2012
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 18.7 years ago
Interventions
Tanezumab 10 mg IVdrug
Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
IV Placebo for tanezumabdrug
Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.